Tonix Q1 net loss $40.2M; TONMYA launch generates $3.7M revenue with 2,145 prescribers

Tonix Pharmaceuticals Holding Corp.

2026-Q1 EPS reported -$2.93 vs consensus -$2.48 ▼ miss (-18.0%)

Net product revenue $6.9M (TONMYA $3.7M, legacy products $3.2M); net loss $40.2M ($2.93/share).
Cash $185.5M at Mar 31; raised $22.6M post-quarter via ATM; runway into early Q2 2027.
TONMYA Q1: 2,145 HCPs prescribed, 3,588 patients initiated, ~5,400 Rx; cumulative 11,016 Rx through May 1.
Secured GPO agreement covering ~35M commercial lives; Medicaid coverage in 38 states (~55M lives).
TNX-4800 Phase 2 Lyme prevention study planned for 2027; TNX-102 SL MDD Phase 2 to start mid-2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tonix Pharmaceuticals Holding Corp. reported financial results for the quarter ended March 31, 2026.

Period: the quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 11, 2026, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter ended March 31, 2026. A copy of the press release that discusses these matters is filed as Exhibit 99.01 to, and incorporated by reference in, this report.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Tonix Pharmaceuticals Holding Corp. filing history →

Source: SEC EDGAR

accession 0001999371-26-010487

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.